IntraGel Therapeutics is a groundbreaking brand that specializes in continuous and smart therapy for fighting tumors. Their innovative technology allows for the local treatment of tumors using safe and slow-release anti-cancer drugs. This approach addresses a critical need in the field of oncology, as many patients experience extreme side effects from traditional chemotherapy treatments.

In fact, approximately 30% of oncology patients and 50% of head and neck cancer patients are deemed unfit for treatment due to their low BMI and general health condition. IntraGel's solution involves intratumoral, safe, and sustained release of chemotherapy drugs through a honey-like gel. This gel can be easily mixed with therapeutic agents and injected directly into the tumor or desired site.

Once in place, the gel solidifies and gradually disintegrates over weeks, releasing the drug in a controlled and prolonged manner. This approach maximizes the therapeutic effects of the drugs while minimizing severe side effects. IntraGel's pre-filled syringe contains an anti-cancer drug formulated into a hydrophobic, biocompatible, and biodegradable honey-like polymer.

They are currently finalizing their dossier for first-in-human trials, focusing on advanced-stage head and neck cancer patients. Furthermore, their technology has the potential to be applied to a wide range of anti-cancer drugs and various types of solid tumors. IntraGel Therapeutics is giving unfit patients a second chance to fight back against cancer with their continuous and targeted therapy approach